Workflow
Medical
icon
搜索文档
Carlsmed: Spine Play Does Not Have My Backing Yet
Seeking Alpha· 2025-07-24 16:14
If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!Shares of Carlsmed (NASDAQ: CARL ) have seen a calm debut, trading around the public offering price on the first day of trading. Investors are not necessarily convinced on the personalized spine s ...
AI Chat With Roland Rott, President & CEO of Imaging at GE HealthCare
The Motley Fool· 2025-07-24 12:23
A set of AI use cases within the medical space.In this podcast Motley Fool analysts David Meier and Asit Sharma and GE HealthCare's CEO of Imaging, Roland Rott, discuss:The latest on GE Healthcare.How AI is used to create efficiency gains.How AI is used to boost patient outcomes.To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. When you're ready to invest, check out this top 10 list of stocks to buy.A full transcript is below. This podcast was recorded on July 20, ...
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against RxSight, Inc. (RXST)
GlobeNewswire News Room· 2025-07-24 08:00
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of all persons or entities who purchased the securities of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants failed to disclose to investors that: (i) the Compan ...
RXSIGHT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against RxSight, Inc. and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2025-07-24 06:57
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In RxSight (RXST) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in RxSight between November 7, 2024 and July 8, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholde ...
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
ZACKS· 2025-07-24 06:51
股价表现 - 公司股价在最近交易日收于47695美元,单日涨幅145%,表现优于标普500指数的078%涨幅[1] - 过去一个月股价累计上涨441%,跑赢医疗行业同期002%的跌幅,但落后于标普500同期588%的涨幅[1] - 同期道琼斯指数上涨114%,纳斯达克指数上涨061%[1] 业绩预期 - 预计2025年8月4日发布的季度EPS为424美元,同比大幅增长13305%[2] - 季度收入预计达289亿美元,同比增长923%[2] - 全年EPS预期1778美元,同比激增413333%,全年收入预期1191亿美元,同比增长81%[3] 估值指标 - 公司当前远期市盈率为2644倍,高于行业平均192倍[6] - 所属医疗-生物医学与遗传学行业在Zacks行业排名中位列第92,处于全行业前38%分位[6] 分析师评级 - Zacks综合评级为3级(持有),过去一个月EPS共识预期微降006%[5] - 行业排名前50%的组别平均表现是后50%的两倍[7] 行业地位 - 医疗-生物医学与遗传学行业属于医疗板块,包含250多个细分行业[6] - Zacks行业排名通过计算组内个股评级的平均值确定行业强度[7]
Molina (MOH) Q2 Earnings Miss Estimates
ZACKS· 2025-07-24 06:31
Molina (MOH) came out with quarterly earnings of $5.48 per share, missing the Zacks Consensus Estimate of $5.5 per share. This compares to earnings of $5.86 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -0.36%. A quarter ago, it was expected that this provider of Medicaid-related services would post earnings of $5.86 per share when it actually produced earnings of $6.08, delivering a surprise of +3.75%.Over the last four qua ...
RXST INVESTOR ALERT: RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Prnewswire· 2025-07-24 05:36
公司诉讼案件 - RxSight公司面临集体诉讼 指控其高管违反1934年证券交易法 [1] - 诉讼指控公司在整个报告期内做出虚假或误导性陈述 未披露销售下滑和产品需求被夸大等问题 [4] - 公司2025年第二季度初步财报显示 光传输设备销售额和可调节晶体使用率显著下降 全年收入指引下调4250万美元 [5] 公司业务 - RxSight是商业化阶段医疗技术公司 专注于白内障手术用可调节晶体的研发制造和销售 [3] - 公司CEO承认过去几个季度的市场接受度挑战是光传输设备销售停滞的主要原因 [5] 市场反应 - 负面财报公布后 RxSight股价单日暴跌近38% [5] 律所信息 - Robbins Geller律所在证券欺诈诉讼领域领先 2024年为投资者追回25亿美元赔偿 [7] - 该律所曾创下72亿美元证券集体诉讼赔偿纪录 [7]
RxSight, Inc. Investors: Company Investigated by the Portnoy Law Firm
GlobeNewswire News Room· 2025-07-24 04:56
Investors can contact the law firm at no cost to learn more about recovering their losses​ LOS ANGELES, July 23, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. RxSight investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Les ...
TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference
Globenewswire· 2025-07-24 04:03
MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 45th Annual Growth Conference. TELA’s management is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference at 10:00 am ET on August 13th, 2025. Interested parties can access the live and archived webcast at ir.telabio.com ...
Boston Sci Q2 Revenue Up 23 Percent
The Motley Fool· 2025-07-24 02:52
Boston Scientific (BSX 4.21%), a leader in medical devices for cardiovascular and surgical markets, reported its second-quarter 2025 results on July 23, 2025. The company posted revenue and earnings well above Wall Street expectations for the period, with revenue of $5.06 billion topping analyst estimates of $4.89 billion. Adjusted (non-GAAP) earnings per share (EPS) landed at $0.75, also ahead of the projected $0.73. Both numbers exceeded the upper end of Boston Scientific's own guidance. Management charac ...